Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 6575

Sort by

Sort Order Select

Journal Articles

Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL

Qi Han, Yan Gu, Huimin Xiang, Linyao Zhang, Yan Wang, Chan Yang, Jun Li, Chelsea Steiner, Rosa Lapalombella, Jennifer A. Woyach, Yiping Yang, Sinisa Dovat, Chunhua Song, Zheng Ge

Blood (2025) 145 (13): 1407–1421.

https://doi.org/10.1182/blood.2024024130

Published: 2025

Includes: Supplemental data

Journal Articles

α-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia

Scott E. Millman, Almudena Chaves-Perez, Sudha Janaki-Raman, Yu-Jui Ho, John P. Morris, IV, Varun Narendra, Chi-Chao Chen, Benjamin T. Jackson, Jossie J. Yashinskie, Riccardo Mezzadra, Tessa I. Devine, Valentin J. A. Barthet, Michelle Saoi, Timour Baslan, Sha Tian, Zohar Sachs, Lydia W. S. Finley, Justin R. Cross, Scott W. Lowe

Blood (2025) 145 (13): 1422–1436.

https://doi.org/10.1182/blood.2024025245

Published: 2025

Includes: Supplemental data

Journal Articles

Sickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review

Lachelle D. Weeks, Allecia M. Wilson, Rakhi P. Naik, Yvonne Efebera, M. Hassan Murad, Anjlee Mahajan, Patrick T. McGann, Madeleine Verhovsek, Angela C. Weyand, Ahmar U. Zaidi, Michael R. DeBaun, Chancellor Donald, Roger A. Mitchell

Blood (2025) 145 (13): 1345–1352.

https://doi.org/10.1182/blood.2024026899

Published: 2025

Includes: Supplemental data

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Journal Articles

Atypical chronic myeloid leukemia: from cytology to molecular characterization

Aida Calo-Pérez, Raquel Martínez-Fernández

Blood (2025) 145 (13): 1438.

https://doi.org/10.1182/blood.2024027505

Published: 2025

Journal Articles

Taming JAK cytokine release in haplo-transplant

Nikolas von Bubnoff

Blood (2025) 145 (13): 1336–1338.

https://doi.org/10.1182/blood.2024027588

Published: 2025

Journal Articles

Two is better than one: dual targeting of WDR5 in T-ALL

Alexander A. Wurm, Denis M. Schewe

Blood (2025) 145 (13): 1339–1341.

https://doi.org/10.1182/blood.2024027633

Published: 2025

Journal Articles

Jumping barriers in clinical trials: release the brake

Lionel Adès

Blood (2025) 145 (13): 1335–1336.

https://doi.org/10.1182/blood.2024027711

Published: 2025

Journal Articles

Targeting an AML-sustaining metabolic node

Sarada Achyutuni, Jian Xu

Blood (2025) 145 (13): 1341–1343.

https://doi.org/10.1182/blood.2024027768

Published: 2025

Journal Articles

PGE 2 inhibition to prevent AML escape from NK cells

Federico Simonetta

Blood (2025) 145 (13): 1338–1339.

https://doi.org/10.1182/blood.2024027931

Published: 2025

Journal Articles

Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma

Tanner J. Bakhshi, Sergio Pina-Oviedo

Blood (2025) 145 (13): 1437.

https://doi.org/10.1182/blood.2024028017

Published: 2025

Journal Articles

Population dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases

Apeksha Singh, Jennifer J. Chia, Dinesh S. Rao, Alexander Hoffmann

Blood (2025) 145 (12): 1293–1308.

https://doi.org/10.1182/blood.2024025598

Published: 2025

Includes: Supplemental data

Journal Articles

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Blood (2025) 145 (12): 1282–1292.

https://doi.org/10.1182/blood.2024026685

Published: 2025

Includes: Supplemental data

Journal Articles

Complement ing CD20 antibodies’ effector functions

Jeanette Leusen, Thomas Valerius

Blood (2025) 145 (12): 1232–1234.

https://doi.org/10.1182/blood.2024027767

Published: 2025

Journal Articles

Introduction to a How I Treat series on acute myeloid leukemia

Selina M. Luger

Blood (2025) 145 (12): 1227–1228.

https://doi.org/10.1182/blood.2024027264

Published: 2025

Journal Articles

LSS-Skin Sclerosis: key addition to cGVHD assessments

Najla El Jurdi, Steven Z. Pavletic

Blood (2025) 145 (12): 1234–1235.

https://doi.org/10.1182/blood.2025028352

Published: 2025

Journal Articles

Math models expose myeloid bias mechanisms in hematopoiesis

Artur C. Fassoni, Ingmar Glauche

Blood (2025) 145 (12): 1231–1232.

https://doi.org/10.1182/blood.2024027777

Published: 2025

Journal Articles

Megakaryocyte mitotic figures in de novo AML, myelodysplasia related, with STAG2, SRSF2, and ASXL1 comutations

Zhaodong Xu, Kristine Roland

Blood (2025) 145 (12): 1333.

https://doi.org/10.1182/blood.2024027590

Published: 2025

Journal Articles

Triplets: the bright and the dark side of the moon

Anna Maria Frustaci, Alessandra Tedeschi

Blood (2025) 145 (12): 1229–1231.

https://doi.org/10.1182/blood.2024028110

Published: 2025

Journal Articles

Zanubrutinib, venetoclax, and obinutuzumab in R/R CLL

Blood (2025) 145 (12): 1334.

https://doi.org/10.1182/blood.2025028638

Published: 2025

NARROW

Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL

α-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia

Sickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Atypical chronic myeloid leukemia: from cytology to molecular characterization

Taming JAK cytokine release in haplo-transplant

Two is better than one: dual targeting of WDR5 in T-ALL

Jumping barriers in clinical trials: release the brake

Targeting an AML-sustaining metabolic node

PGE 2 inhibition to prevent AML escape from NK cells

Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma

Population dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Complement ing CD20 antibodies’ effector functions

Introduction to a How I Treat series on acute myeloid leukemia

LSS-Skin Sclerosis: key addition to cGVHD assessments

Math models expose myeloid bias mechanisms in hematopoiesis

Megakaryocyte mitotic figures in de novo AML, myelodysplasia related, with STAG2, SRSF2, and ASXL1 comutations

Triplets: the bright and the dark side of the moon

Zanubrutinib, venetoclax, and obinutuzumab in R/R CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only